Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006490 · ClinicalTrials.gov registry record

A Comparison of Two Tests for Anti-HIV Drug Resistance

A clinical trial of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
600
Enrollment target
20
Study locations

NCT00006490 is a study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 600 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006490, a study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
600 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to compare 2 different types of tests of the HIV virus to see which specific anti-HIV drugs would work the best. Drug resistance is a major reason for therapy failure in HIV patients. Two types of tests can detect resistance to drugs: 1) genotyping (sequencing), which looks at the DNA sequence of a virus to see whether it has developed any genetic resistance; 2) phenotyping, which looks at the ability of different drugs to suppress virus growth in the laboratory. Genotyping and phenotyping can help doctors give patients the most effective drug therapy.

Conditions Studied

HIV Infections

Study Locations (20)

California

  • Univ of Southern California / LA County USC Med Ctr - Los Angeles
  • UCLA CARE Ctr - Los Angeles
  • Willow Clinic - Menlo Park
  • University of California San Francisco - San Francisco
  • Univ of California San Francisco - San Francisco
  • Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium - San Jose
  • San Mateo AIDS Program / Stanford Univ - Stanford
  • Stanford Univ Med Ctr - Stanford
  • Harbor UCLA Med Ctr - Torrance

Illinois

  • Northwestern Univ Med School - Chicago
  • Rush Presbyterian - Saint Luke's Med Ctr - Chicago
  • The CORE Ctr - Chicago

Colorado

  • Denver Dept of Health and Hosps - Denver
  • Univ of Colorado Health Sciences Ctr - Denver

Alabama

  • Univ of Alabama at Birmingham - Birmingham

Florida

  • Univ of Miami School of Medicine - Miami

Georgia

  • Emory Univ - Atlanta

Hawaii

  • Univ of Hawaii - Honolulu

Maryland

  • Johns Hopkins Hosp - Baltimore

Trial Details

FieldValue
Enrollment Target 600 participants

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00006490

The ClinicalTrials.gov registry entry for NCT00006490 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (35% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 0 interventions.

NCT00006490 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Illinois, Colorado.

Frequently Asked Questions

What is clinical trial NCT00006490 about?

NCT00006490 is a clinical study titled "A Comparison of Two Tests for Anti-HIV Drug Resistance". The purpose of this study is to compare 2 different types of tests of the HIV virus to see which specific anti-HIV drugs would work the best. Drug resistance is a major reason for therapy failure in HIV patients. Two types of tests can detect resistance to drugs: 1) genotyping (sequencing), which l...

What is the current status of trial NCT00006490?

This trial is currently completed. The enrollment target is 600 participants.

What conditions does trial NCT00006490 study?

This clinical trial studies the following conditions: HIV Infections.

Who is sponsoring clinical trial NCT00006490?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006490 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.